Back to Search
Start Over
Patients with advanced hepatocellular carcinoma need a personalized management: A lesson from clinical practice
- Publication Year :
- 2018
-
Abstract
- The Barcelona Clinic Liver Cancer advanced stage (BCLC C) of hepatocellular carcinoma (HCC) includes a heterogeneous population, where sorafenib alone is the recommended treatment. In this study our aim was to assess treatment and overall survival (OS) of BCLC C patients sub-classified according to clinical features (Performance Status [PS], macro-vascular invasion [MVI], extra-hepatic spread [EHS] or MVI+EHS) determining their allocation to this stage. From the Italian Liver Cancer database, we analysed 835 consecutive BCLC C patients diagnosed between 2008 and 2014. Patients were sub-classified as: PS1 alone (n=385, 46.1%), PS2 alone (n=146, 17.5%), MVI (n=224, 26.8%), EHS (n=51, 6.1%) and MVI+EHS (n=29, 3.5%). MVI, EHS and MVI+EHS patients had larger and multifocal/massive HCCs and higher alpha-fetoprotein levels than PS1 and PS2 patients. Median OS significantly declined from PS1 (38.6 months) to PS2 (22.3 months), EHS (11.2 months), MVI (8.2 months) and MVI+EHS (3.1 months) (P
- Subjects :
- Sorafenib
Male
medicine.medical_specialty
Carcinoma, Hepatocellular
Databases, Factual
Settore MED/12 - GASTROENTEROLOGIA
advanced stage
Gastroenterology
survival
03 medical and health sciences
Liver disease
0302 clinical medicine
Internal medicine
medicine
Carcinoma
Humans
Stage (cooking)
Precision Medicine
Cancer staging
Aged
Neoplasm Staging
Retrospective Studies
Aged, 80 and over
therapy
Hepatology
Performance status
business.industry
Liver Neoplasms
Middle Aged
medicine.disease
Prognosis
Survival Analysis
Liver cancer
sorafenib
Liver cancer, advanced stage, sorafenib, survival, therapy
Treatment Outcome
Liver
030220 oncology & carcinogenesis
Hepatocellular carcinoma
030211 gastroenterology & hepatology
Female
alpha-Fetoproteins
business
medicine.drug
Subjects
Details
- Language :
- English
- Database :
- OpenAIRE
- Accession number :
- edsair.doi.dedup.....9a9229a7b49ea14b6ed47a849a9adbac